tirzepatide class of drugs Patients who took the anti-obesity drug for almost two years lost 25 percent their body weight and maintained improvements in metabolic and cardiovascular health, according to a new phase 3 F.D.A. Approves New Obesity Drug

1 0.1 10

Cagrilintide monotherapy uses up to 4.5 mg weekly, while retatrutide reaches 12 mg weekly, but combining these maximum doses would almost certainly be unsafe

FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list The vote is non-binding and will still need sign off from the FDA

T.NicklasJ

Mild to moderate pain Protocol: BPC-157: 250mcg twice daily Duration: 4-8 weeks Method: Injectable near pain site or systemic Expected outcome: 40-60% pain reduction Improved function May be sufficient alone Severe or chronic pain Protocol: BPC-157: 500mcg twice daily TB-500: 5-10mg weekly loading for 4-6 weeks, then 2-5mg maintenance Duration: 12-16 weeks minimum Method: Injectable Expected outcome: 50-70% pain reduction Significant functional improvement Better quality of life Multiple pain sites or systemic pain Protocol: BPC-157: 250-500mcg twice daily (systemic injections - abdomen/thighs) TB-500: 5mg weekly Optional: KPV 500mcg daily if inflammation major factor Duration: 12-24 weeks Expected outcome: 40-60% overall pain reduction Improved multiple areas Better mobility Maintenance protocol After initial relief: BPC-157: 250mcg daily OR every other day TB-500: 2-5mg weekly OR biweekly Duration: Ongoing as needed Why maintenance: Prevents pain return Continues healing Safe long-term Use our peptide dosing guide , peptide dosage chart , and how to calculate peptide dosages

PT-141 , Bremelanotide , was derived directly from MT-II through C-terminal amide hydrolysis, producing a compound that retains the cyclic heptapeptide structure and MC3R/MC4R pro-sexual activity while reducing MC1R-mediated tanning